Genprex Inc
GNPX
NASDAQ
Biotechnology
$4.32
USD
-0.55 (-11.29%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $2.53M
Volume 90.4K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-16.73M
TTM
+12.5%
YoY
Operating Cash Flow
$-14.29M
TTM
+14.9%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 1.4 | 2.2 | 1.2 | 1.3 | 1.7 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 4.0 | 4.7 | 3.3 | 3.5 | 4.5 |
Operating Income | -4.0 | -4.7 | -3.3 | -3.5 | -4.5 |
EBITDA | -4.0 | -4.7 | -3.3 | -3.5 | -4.5 |
Other Income / Expense | -0.0 | 0.0 | -0.5 | -0.3 | 0.0 |
Total Other Income / Expense | 0.0 | 0.0 | -0.5 | -0.3 | 0.0 |
Income Before Income Taxes | -4.0 | -4.7 | -3.8 | -3.8 | -4.5 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -4.0 | -4.7 | -3.8 | -3.8 | -4.5 |
Consolidated Net Income / Loss | -4.0 | -4.7 | -3.8 | -3.8 | -4.5 |
Net Income Attributable to Common Shareholders | -4.0 | -4.7 | -3.8 | -3.8 | -4.5 |
Basic EPS | -$285.56 | -$187.00 | -$110.00 | -$39.46 | -$14.08 |
Diluted EPS | -$285.56 | -$187.00 | -$110.00 | -$39.46 | -$14.08 |
Basic Shares Outstanding | 0.0M | 0.0M | 0.0M | 0.1M | 0.3M |
Diluted Shares Outstanding | 0.0M | 0.0M | 0.0M | 0.1M | 0.3M |